Navigation Links
International space station plays host to innovative infectious disease research
Date:2/18/2013

Performing sensitive biological experiments is always a delicate affair. Few researchers, however, contend with the challenges faced by Cheryl Nickerson, whose working laboratory aboard the International Space Station (ISS) is located hundreds of miles above the Earth, traveling at some 17,000 miles per hour.

Nickerson, a microbiologist at Arizona State University's Biodesign Institute, is using the ISS platform to pursue new research into the effects of microgravity on disease-causing organisms.

Nickerson presented her research findings and charted the course for future investigations aboard the ISS on February 18 at the 2013 annual meeting for the American Association for the Advancement of Science, held in Boston, Mass. Her talk, entitled "Microgravity: A Novel Tool for Advances in Biomedical Research," is part of a special session devoted to ISS science.

"One important focus of my research is to use the microgravity environment of spaceflight as an innovative biomedical research platform. We seek to unveil novel cellular and molecular mechanisms related to infectious disease progression that cannot be observed here on Earth, and to translate our findings to novel strategies for treatment and prevention."

During an earlier series of NASA space shuttle and ground-based experiments, Nickerson and her team made a startling discovery. Spaceflight culture increased the disease-causing potential (virulence) of the foodborne pathogen Salmonella, yet many of the genes known to be important for its virulence were not turned on and off as expected when this organism is grown on Earth. Understanding how this switching is regulated may be useful for designing targeted strategies to prevent infection.

For NASA, Nickerson's findings were revelatory, given their implications for the health of astronauts on extended spaceflight missions. Already faced with the potential for compromised immunity induced by the rigors of space tra
'/>"/>

Contact: Joe Caspermeyer
joseph.caspermeyer@asu.edu
480-727-0369
Arizona State University
Source:Eurekalert

Page: 1 2 3 4 5 6

Related biology news :

1. Maris presentation tops ANZFSS International Symposium
2. International biodiversity data symposium to mark the kickoff of the EU BON project
3. AERA announces publication of the International Handbook of Research on Environmental Education
4. Conference Programme Committees selected for the 20th International AIDS Conference (AIDS 2014)
5. Winners of 10th annual International Science & Technology Visualization Challenge announced
6. The 2013 International Conference on Genomics in Europe will take place in Ghent, Belgium
7. Flashback Data Remains Only Non-Governmental Digital Forensics Lab with ASCLD/LAB International Accreditation
8. International study: Where theres smoke or smog, theres climate change
9. Biophysical Society announces winners of 2013 international travel awards
10. International study suggests human genes influence gut microbial composition
11. U of M to lead international virtual institute studying climatic and human effects on Earth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... (Sept. 17, 2014) A rare genetic disorder known as ... a recent joint investigation by researchers at San Diego ... In addition to suggesting better treatment options for people ... into the genetic underpinnings of autism., Jacobsen syndrome affects ... Institutes of Health. It occurs in a person when ...
(Date:9/17/2014)... Mar Medical Research Institute) and at the Universitat Politcnica ... eLife showing that RNA called non-coding (IncRNA) ... proteins, some of which could have important cell functions ... instructions found in an RNA molecule. However, only 2% ... the synthesis of proteins, meaning it is coding. Other ...
(Date:9/17/2014)... 17, 2014 Researchers at UTSouthwestern Medical Center have ... protein apolipoprotein E, called apoE3, helps repair the lining ... do not get the benefit of this repair, putting ... believe that we have identified one mechanism by which ... genetic variant, apoE4, is detrimental," said Dr. Philip ...
Breaking Biology News(10 mins):A link between Jacobsen syndrome and autism 2Parts of genome without a known function may play a key role in the birth of new proteins 2Protein variant may boost cardiovascular risk by hindering blood vessel repair 2
... and use of commercial fertilisers and animal waste is ... our aquatic environment. Yet global food and bioenergy supplies ... Agriculture and Ecology at LIFE Faculty of Life ... massive resources at the development of sustainable animal waste ...
... a popular species of game fish in Lake Erie are ... most comprehensive to date on mercury levels in Great Lakes ... a semi-monthly journal. Satyendra Bhavsar and colleagues note ... lakes in the world. The lakes are of significant economic ...
... 20, 2010) -- The Howard Hughes Medical Institute (HHMI) ... Rice University,s successful undergraduate global health program Beyond Traditional ... million HHMI grant in 2006, challenges students to come ... developing world. The program has captured the imagination of ...
Cached Biology News:Massive resources now directed at sustainable animal waste technology 2HHMI renews grant for Rice's global health program 2
(Date:9/18/2014)... 2014 September 24 marks ASEA's "Meet ... is the manufacturer of the world's first and only ... RENU28. , The Mexico City event features renowned ... and ASEA Field Leader Shawn Catmull from Draper, UT. ... Atomic/Medical Physics from the University of Utah and devotes ...
(Date:9/17/2014)... A long-term retrospective study of breast ... via interstitial brachytherapy suggests that women younger than ... be suitable to receive the treatment. Current American ... patients in the "unsuitable" category for APBI. In ... Beaumont Health System,s Peter Y. Chen , ...
(Date:9/17/2014)... 17, 2014  The In Silico Drug Discovery Conference ... featured at the conference, which takes place at North ... and 4, 2014. Researchers, students, drug developers, business development ... following: KEYNOTE SPEAKERS ... School of Pharmacy Drug Discovery with Three ...
(Date:9/17/2014)... , Sept. 17, 2014  MiMedx Group, Inc. (NASDAQ: ... and marketer of patent protected regenerative biomaterials and ... publication of another peer-reviewed clinical study.    ... Multi-center Randomized Controlled Clinical Trial Evaluating the Use ... Allografts and Multi-layer Compression Therapy vs. Multi-layer Compression ...
Breaking Biology Technology:Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4In Silico Drug Discovery Conference Announces Speakers and Topics 2In Silico Drug Discovery Conference Announces Speakers and Topics 3In Silico Drug Discovery Conference Announces Speakers and Topics 4In Silico Drug Discovery Conference Announces Speakers and Topics 5In Silico Drug Discovery Conference Announces Speakers and Topics 6In Silico Drug Discovery Conference Announces Speakers and Topics 7MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4
... ... ... ... March 12 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) today announced that it will restate its 2008 financial statements contained in its Annual Report on Form 10-K for the ...
... LAKE, N.J. , March 11 Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen ... , ... , , ... ...
... China , March 11 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical Co., Inc. ... ("TCM") based in Chengdu, China , today,announced it will present ... held March 15-17, 2010 in Dana Point, California ... Tuesday, March 16, 2010, ...
Cached Biology Technology:Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 2Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 3Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 4Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 5Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 6Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 7Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 8Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 9Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 10FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 2FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 3FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 4FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 5FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 6FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 7FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 8Tianyin Pharmaceutical Co., Inc. to Present at the 22nd Annual ROTH Capital Partners OC Growth Stock Conference on March 16 2Tianyin Pharmaceutical Co., Inc. to Present at the 22nd Annual ROTH Capital Partners OC Growth Stock Conference on March 16 3Tianyin Pharmaceutical Co., Inc. to Present at the 22nd Annual ROTH Capital Partners OC Growth Stock Conference on March 16 4
...
TNM-FH Insect Medium 1 liter...
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
Performance, mycoplasma, virus, and endotoxin tested. Collected from calves 14 days old or less...
Biology Products: